ANRO
Alto Neuroscience, Inc. NYSE Listed Feb 2, 2024$22.93
Mkt Cap $661.6M
52w Low $2.20
81.2% of range
52w High $27.72
50d MA $22.89
200d MA $16.44
P/E (TTM)
—
EV/EBITDA
—
P/B
4.4x
Debt/Equity
0.0x
ROE
-41.8%
P/FCF
-12.8x
RSI (14)
62.30
ATR (14)
$1.67
Beta
2.06
50d MA
$22.89
200d MA
$16.44
Avg Volume
346.6K
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
369 South San Antonio Road · Mountain View, CA 94022 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | TNS | -0.56 | -0.80 | -42.9% | 22.85 | -3.7% | +3.2% | -2.6% | -5.1% | -6.2% | +1.6% | — |
| Mar 16, 2026 | TNS | -0.56 | -0.45 | +19.6% | 24.29 | +0.1% | -7.9% | +0.7% | -2.1% | -2.6% | -6.8% | — |
| Nov 12, 2025 | TNS | -0.66 | -0.52 | +21.2% | 14.20 | +1.8% | -20.1% | +6.7% | +14.0% | +6.9% | +5.4% | — |
| Aug 13, 2025 | TNS | -0.57 | -0.65 | -14.0% | 3.13 | -1.9% | -0.3% | +0.6% | +8.6% | +0.6% | +0.0% | — |
| May 14, 2025 | TNS | -0.59 | -0.53 | +10.2% | 2.20 | +0.0% | +10.5% | +4.1% | +0.4% | +14.6% | -2.1% | — |
| Mar 20, 2025 | TNS | -0.65 | -0.56 | +13.8% | 2.69 | -2.2% | -1.5% | +0.0% | -4.5% | -1.2% | -3.6% | — |
| Nov 12, 2024 | TNS | -0.67 | -0.62 | +7.5% | 4.50 | +2.7% | +0.7% | +1.5% | -1.7% | +1.8% | -2.6% | — |
| Aug 13, 2024 | TNS | -0.71 | -0.60 | +15.5% | 8.98 | +0.2% | +6.0% | -1.5% | -0.2% | +8.2% | -0.5% | — |
| May 14, 2024 | TNS | -0.46 | -0.76 | -65.2% | 14.16 | -1.1% | -2.3% | -7.4% | -2.7% | -0.6% | +2.3% | — |
| Mar 21, 2024 | TNS | -1.67 | -7.77 | -365.3% | 15.15 | -2.0% | +5.4% | +4.3% | +7.8% | -6.5% | -8.5% | — |
| Feb 5, 2024 | TNS | — | -0.34 | — | 21.80 | -4.1% | -11.1% | -2.1% | +0.0% | -12.8% | -15.8% | — |
| Jun 29, 2023 | TNS | — | -0.32 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.27 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | Wolfe Research | Initiates | Outperform | — | $21.54 | $21.69 | +0.7% | -1.5% | -0.8% | -2.9% | -1.1% | -0.7% |
| May 5 | BofA Securities | Initiates | Buy | $35 | $25.19 | $25.91 | +2.9% | +1.0% | -3.8% | -1.7% | +0.8% | +1.1% |
| Apr 22 | Chardan Capital | Maintains | Buy → Buy | — | $25.59 | $26.22 | +2.5% | +6.1% | -5.3% | -4.6% | -1.0% | +0.8% |
| Apr 2 | Jones Trading | Maintains | Buy → Buy | — | $23.41 | $20.00 | -14.6% | -7.4% | +3.9% | -5.2% | +1.7% | +3.2% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.41 | $20.00 | -14.6% | -7.4% | +3.9% | -5.2% | +1.7% | +3.2% |
| Apr 2 | Wedbush | Maintains | Neutral → Neutral | — | $23.41 | $20.00 | -14.6% | -7.4% | +3.9% | -5.2% | +1.7% | +3.2% |
| Apr 2 | Chardan Capital | Maintains | Buy → Buy | — | $23.41 | $20.00 | -14.6% | -7.4% | +3.9% | -5.2% | +1.7% | +3.2% |
| Apr 2 | Baird | Maintains | Outperform → Outperform | — | $23.41 | $20.00 | -14.6% | -7.4% | +3.9% | -5.2% | +1.7% | +3.2% |
| Mar 18 | Baird | Maintains | Outperform → Outperform | — | $22.36 | $22.66 | +1.3% | +0.7% | -2.1% | -2.6% | -6.8% | +0.8% |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | $24.29 | $24.32 | +0.1% | -7.9% | +0.7% | -2.1% | -2.6% | -6.8% |
| Mar 17 | Wedbush | Maintains | Neutral → Neutral | — | $24.29 | $24.32 | +0.1% | -7.9% | +0.7% | -2.1% | -2.6% | -6.8% |
| Feb 17 | BTIG | Maintains | Buy → Buy | — | $16.89 | $16.63 | -1.5% | +14.0% | -5.9% | +7.6% | -9.6% | +3.9% |
| Jan 5 | Chardan Capital | Maintains | Buy → Buy | — | $16.59 | $16.63 | +0.2% | -0.4% | -8.8% | +6.1% | -0.7% | +3.0% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $14.20 | $14.45 | +1.8% | -20.1% | +6.7% | +14.0% | +6.9% | +5.4% |
| Nov 12 | Jefferies | Maintains | Buy → Buy | — | $13.40 | $13.40 | +0.0% | +6.0% | -20.1% | +6.7% | +14.0% | +6.9% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.18 | $11.65 | +4.2% | -1.6% | +11.4% | +11.2% | +3.1% | +2.0% |
| Oct 20 | Baird | Maintains | Outperform → Outperform | — | $6.08 | $6.75 | +11.0% | +80.9% | -1.4% | -6.0% | +9.6% | -1.6% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.14 | $3.07 | -2.2% | +8.6% | +0.6% | +0.0% | +4.7% | +8.6% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.38 | -7.4% | -10.5% | +0.4% | -4.8% | +0.9% | +3.6% |
| May 15 | Wedbush | Maintains | Neutral → Neutral | — | $2.20 | $2.20 | +0.0% | +10.5% | +4.1% | +0.4% | +14.6% | -2.1% |
| Nov 13 | Stifel | Maintains | Buy → Buy | — | $4.50 | $4.62 | +2.7% | +0.7% | +1.5% | -1.7% | +1.8% | -2.6% |
| Oct 23 | Wedbush | Downgrade | Outperform → Neutral | — | $14.53 | $5.15 | -64.6% | -70.0% | -5.3% | +5.8% | -3.4% | -5.0% |
| Oct 23 | Baird | Maintains | Outperform → Outperform | — | $14.53 | $5.15 | -64.6% | -70.0% | -5.3% | +5.8% | -3.4% | -5.0% |
| Sep 10 | Wedbush | Maintains | Outperform → Outperform | — | $14.11 | $14.11 | +0.0% | -4.6% | -0.4% | -3.1% | +4.8% | +2.1% |
| Mar 25 | Stifel | Maintains | Buy → Buy | — | $15.97 | $16.13 | +1.0% | +4.3% | +7.8% | -6.5% | -8.5% | -5.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Alto Neuroscience, Inc. -- 8-K 5.02: Executive Change
May 28
8-K · 2.02
!! High
Alto Neuroscience, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Alto Neuroscience's ALTO-101 missed its primary efficacy endpoint (p=0.052), but the company is pursuing partnering deals for a new formulation while advancing ALTO-207 into Phase 2b, signaling pipeline persistence despite setback.
Apr 1
8-K
Unknown — 8-K Filing
Alto Neuroscience's strong financial position and advancing neuropsychiatric pipeline entering 2026 suggests reduced near-term dilution risk, potentially supporting stock valuation for clinical-stage investors betting on therapeutic progress.
Mar 16
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ANRO issued $120M in equity with registration rights, likely diluting existing shareholders but providing near-term capital for operations or acquisitions that could drive future growth.
Mar 16
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alpha Wave Global, Lp | 3,707,757 | $83M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,207,025 | $27M | New | Mar 2026 |
| 3 | Franklin Resources Inc | 1,101,874 | $25M | Reduced | Mar 2026 |
| 4 | Vivo Capital, Llc | 1,035,551 | $23M | New | Mar 2026 |
| 5 | Millennium Management | 821,982 | $18M | Added | Mar 2026 |
| 6 | 72 Investment Holdings, Llc | 667,778 | $12M | — | Dec 2025 |
| 7 | Point72 Asset Management | 503,087 | $11M | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 473,403 | $11M | — | Mar 2026 |
| 9 | Alkeon Capital Management Llc | 477,101 | $8M | — | Dec 2025 |
| 10 | Susquehanna International Group, Llp | 238,498 | $5M | Added | Mar 2026 |
| 11 | Two Sigma Investments, Lp | 216,099 | $5M | Added | Mar 2026 |
| 12 | Qube Research & Technologies Ltd | 209,268 | $5M | Added | Mar 2026 |
| 13 | Marshall Wace, Llp | 176,347 | $4M | Reduced | Mar 2026 |
| 14 | Jane Street Group, Llc | 194,041 | $3M | Added | Dec 2025 |
| 15 | Morgan Stanley | 131,162 | $2M | Added | Dec 2025 |
| 16 | Renaissance Technologies Llc | 103,499 | $2M | Added | Mar 2026 |
| 17 | Acadian Asset Management Llc | 60,076 | $1M | Added | Mar 2026 |
| 18 | D.e. Shaw & Co | 45,343 | $1M | Reduced | Mar 2026 |
| 19 | Quantinno Capital Management Lp | 36,069 | $811K | Added | Mar 2026 |
| 20 | Hudson Bay Capital Management Lp | 34,789 | $619K | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$661.6M
Enterprise Value
$488.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.65x
P/B
4.38x
P/S
—
P/FCF
-12.77x
EV/EBITDA
—
Shares Out
28.9M
Financials (TTM)
Revenue
$0
Net Income
-$74.3M
EBITDA
-$71.3M
Free Cash Flow
-$51.8M
Op Cash Flow
-$51.8M
EPS Basic
$-2.19
EPS Diluted
$-2.48
EPS Forward
$-2.42
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$184.7M
Total Liab.
$33.5M
Total Equity
$151.1M
Cash
$176.5M
LT Debt
$3.8M
Book Value/Sh
$5.24
Debt/Equity
0.03x
Current Ratio
15.69
Quick Ratio
15.69
Returns & Growth
ROE
-41.8%
ROA
-34.2%
ROIC
-38.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+12.4%
Price Returns
2W
-14.9%
1M
-21.8%
3M
+1.9%
6M
+44.9%
12M
+677.9%
Technicals
52W High
$27.72
52W Low
$2.20
50d MA
$22.89
200d MA
$16.44
RSI (14)
62.30
ATR (14)
$1.67
Beta
2.06
Avg Volume
347K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.50
High
$35.00
Low
$28.00
Median
$31.50
Data updated apr 24, 2026 6:14pm
· Source: financialmodelingprep.com